Home  >  News
Clinical Trials + Font Resize -

Scholar Rock announces publication of pharmacological study of SRK-015 to treat muscle atrophy disorders

Cambridge, Massachusetts
Monday, February 5, 2018, 16:00 Hrs  [IST]

Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment, announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.

The preclinical research published by Scholar Rock researchers demonstrates that inhibiting the activation of the latent precursor form of myostatin using monoclonal antibodies offers a potentially superior approach to address this important therapeutic target. The research shows that: The predominant form of myostatin in muscle is the precursor form.  The precursor of myostatin is localized to the extracellular matrix, coating individual muscle fibers. SRK-015, Scholar Rock’s lead drug candidate, binds to the myostatin precursor with exquisite selectivity, avoiding binding to closely related protein growth factors. By binding with high affinity to the myostatin precursor, SRK-015 blocks activation of myostatin, thereby blocking atrophy and promoting increased muscle mass and strength in preclinical models.

Myostatin is a key signaling protein that negatively regulates muscle mass and function. Inhibiting myostatin signaling therefore has the potential to address a wide range of muscle disorders. Traditional approaches, directly targeting myostatin or its receptor on muscle cells, have yielded only limited success in treating muscle wasting disorders. Furthermore, selectivity challenges could limit the broad applicability of these approaches for the treatment of many neuromuscular diseases.

“The results of this study demonstrate the power of focusing therapeutic intervention in growth factor signaling one step upstream of the signaling event,” said Alan J. Buckler, Ph.D., chief scientific officer of Scholar Rock. “By understanding the processing and release of growth factors in the tissue microenvironment, we see a vast opportunity to improve therapeutic outcomes in many severe diseases with serious unmet medical needs. We are particularly excited to further our understanding of myostatin’s role as we begin clinical trials of SRK-015 in the coming months.”

SRK-015 is initially being developed and investigated by Scholar Rock for the improvement of muscle strength and function in patients with Spinal Muscular Atrophy (SMA) with the treatment of additional neuromuscular diseases to follow.

SRK-015 is a selective and local inhibitor of the supracellular activation of latent myostatin. Myostatin, a member of the TGF-beta superfamily of growth factors that is expressed primarily in skeletal muscle cells, is a genetically validated target that regulates muscle mass. Scholar Rock is actively working to advance SRK-015 into clinical trials that will evaluate the potential to improve muscle strength and motor function in patients with Spinal Muscular Atrophy (SMA). Scholar Rock plans to develop SRK-015 both in SMA patients who are on therapies aimed at upregulating the expression of SMN and as monotherapy in certain subpopulations of SMA patients. SRK-015 is an investigational drug candidate. The effectiveness and safety of SRK-015 have not been established and SRK-015 has not been approved by the FDA or any other regulatory agency.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
CPHI18_banner_150x6
CPhI_Japan_150x60_2018
DIRQ_150x60_2018
Pharmabiz: PPM_150x60_2018
CPHI-SEA-2018-150x60-Register-Now-STAT-English-v1
MTWCbanners_150X60_08
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |